Diagnostics
Assay and reagent development for molecular and immunoassay diagnostics — including antigen and antibody design, binder optimisation and assay-grade protein supply for research and clinical laboratories.
Biotechnology · R&D · AI-enabled
Next-generation proteins, engineered with AI.
We are LYT Consultancy.
A biotechnology venture investing in research and development across diagnostics, drug development, therapeutics and vaccine development — and backing the ventures building them.
Sanabis · Kingdom of Bahrain
4Focus areas
AIEnabled discovery
R&DInvestment & support
GCCBase & global reach
Where we invest and where we build
- Diagnostics
- Drug Development
- Therapeutics
- Vaccine Development
- Protein Engineering
- AI-Enabled Discovery
// 01 — The company
We invest in
what comes next.
LYT Consultancy is a biotechnology venture. We put capital into research and development, and we run a support programme for the ventures and institutions working in diagnostics, drug development, therapeutics and vaccine development. Our own development work centres on next-generation proteins, designed and optimised with artificial intelligence.
Better proteins make better diagnostics, better therapeutics and better vaccines. That is where we put our capital and our compute.
- A
R&D investment
Capital into research and development programmes across our four focus areas, from early discovery through to translational work.
- B
A support programme
Practical backing for biotech ventures and research groups — sourcing and laboratory supply, regulatory navigation, and regional market access.
- C
AI-enabled protein design
Computational design, screening and optimisation of next-generation proteins for diagnostics, therapeutics and vaccine development.
- D
Regional base, global reach
Based in Bahrain, working across Saudi Arabia and the wider GCC with international research and manufacturing partners.
// 02 — Focus areas
Four areas,
one biology.
The science underneath is shared. A protein engineered for a diagnostic assay and one engineered for a vaccine candidate are solved with the same tools — which is why we work across all four rather than picking one.
Drug Development
Support for programmes moving from discovery toward candidate selection — target engagement, protein and construct engineering, and the preclinical groundwork that decides whether a programme is fundable.
Therapeutics
Protein and biologic therapeutics — engineering for stability, expression and manufacturability, so a molecule that works at the bench survives the route to a clinical batch.
Vaccine Development
Antigen design and immunogen engineering for vaccine candidates — including structure-guided design of next-generation antigens and the protein supply that development work depends on.
// 03 — Compute in the loop
AI support for
biotech ventures.
Protein design used to be a search problem solved by hand and by luck. It is now a computational one. We apply AI across the design cycle, and we make that capability available to the ventures we back.
Next-generation proteins,
designed with AI.
Sequence and structure models propose candidates; screening narrows them; laboratory results feed back into the next round. The loop is what matters — not any single model.
- 01
Computational design. Structure-guided and sequence-based design of binders, antigens and engineered constructs.
- 02
Screening & optimisation. In-silico ranking for affinity, stability, expression and developability before anything reaches a bench.
- 03
Design–build–test loops. Laboratory results fed back into the models so each cycle starts better informed than the last.
- 04
Venture-side AI support. The same tooling and know-how extended to the ventures in our support programme.
// 04 — The support programme
How we back
a venture.
Capital is rarely the only thing missing. Our programme pairs investment with the operational support that decides whether good science reaches a market.
- 01
Scope
Understanding the science, the stage it has reached, and what is actually blocking the next milestone.
- 02
Diligence
Technical and commercial assessment — the data, the IP position, the route to a regulated product.
- 03
Investment
Capital committed against defined milestones, with the terms and reporting agreed up front.
- 04
Build
AI-supported design cycles, laboratory sourcing and supply, and the hands-on work of getting to a result.
- 05
Scale
Regulatory navigation, distribution and market entry across Bahrain, Saudi Arabia and the wider GCC.
// 05 — How we engage
We sit inside
the loop.
Not a passive cheque. We work between the research that generates a candidate and the market that has to accept it.
- 01
Research & founders
Spin-outs and founders with a candidate.
- 02
LYT Consultancy
Invests, designs with AI, supports.
- 03
Development partners
CROs and manufacturers who take it forward.
- 04
Clinical & diagnostic labs
Where assays and candidates are put to work.
- 05
Market access
Regulatory route and GCC distribution.
// 06 — Who we work with
Founders,
labs, institutions.
Every side of a biotechnology programme needs something different from us.
- 01
Biotech ventures & founders
Investment, AI-supported design capability, and operational support to the next milestone.
- 02
Research institutions
Collaboration on protein design and assay development, plus reliable laboratory supply.
- 03
Clinical & diagnostic laboratories
Assay-grade proteins, reagents, instruments and consumables with assured provenance.
- 04
Manufacturers & principals
A regional route to market for diagnostic, laboratory and medical product lines.
// 09 — Start a conversation
Tell us what
you’re building.
A candidate, a platform, an assay, or a product line looking for a route into the Gulf. We reply to every enquiry with a named point of contact.
- Registered officeLYT Consultancy W.L.L.
786, Road 408, Sanabis
Kingdom of Bahrain - Telephone / WhatsApp
- Focus
Diagnostics · Drug development
Therapeutics · Vaccine development - Reach
Bahrain · Saudi Arabia · GCC · international partners